Pharma BD Deal Intelligence

Merck & Co. Inc. / Schering-Plough Corporation (joint venture, ezetimibe)

2000 · Co-Development · Complete

Announcement Sentiment

Strongly positive

Merck and Schering-Plough formed a 50/50 joint venture (Merck/Schering-Plough Pharmaceuticals) in May 2000 to co-develop and co-market ezetimibe in the US and combination products with Merck's simvastatin. Resulted in Zetia (2002) and Vytorin (2004). Foundation for the 2009 Merck-Schering-Plough merger.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 15yr post-close.

Key facts

Announced May 22, 2000
Closed May 22, 2000
Deal type Co-Development
Therapeutic area Hypercholesterolemia
Indications Hypercholesterolemia
Key assets Ezetimibe (later Zetia and Vytorin)
Mechanism Cholesterol absorption inhibitor (NPC1L1)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals